arGEN-X to collaborate with Bayer
To discover and develop therapeutic antibody candidates
arGEN-X, a Dutch clinical-stage biopharmaceutical company that develops differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, has entered into collaboration with Bayer Pharma, leveraging arGEN-X’s SIMPLE Antibody technology for the discovery and development of therapeutic antibodies.
The partnership centres on a novel approach to addressing complex targets across multiple therapeutic areas that are often intractable by existing antibody platforms.
arGEN-X will apply its SIMPLE Antibody technology to multiple targets submitted by Bayer. The parties will work together to validate human antibody leads in disease-relevant models, with Bayer being responsible for further preclinical and clinical development and commercialisation of therapeutic antibody products.
Under the terms of the agreement, Bayer will pay arGEN-X an undisclosed upfront technology access fee, research support and technical success-based milestones.
The German company will also pay clinical, regulatory and product sales-based milestones as antibody programmes progress through clinical development and registration.
'We look forward to collaborating with arGEN-X and exploring the potential of SIMPLE Antibody technology to complement Bayer‘s efforts in the discovery and development of first-in-class therapeutic antibodies,' said Harald Dinter, Head of Global Biologics at Bayer Pharma.